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Abstract 
Pertussis, commonly called whooping cough, is a contagious disease, which has 
seen a substantial rise in epidemic proportions during 2011. The respiratory infection, 
which causes a severe uncontrollable cough in any age group, can cause severe 
complications in infants and elderly. The diphtheria toxoid and acelluar pertussis (Tdap) 
vaccine is the most effective protection strategy for preventing the disease. The purpose 
of this study was to determine if preteens and adults are screened and given the Tdap 
vaccine. A retrospective chart review was the design used to provide data for the 
research. The theoretical framework used for the research was the Health Promotion and 
Disease Prevention model by Nola J. Pender. Research questions included the following: 
Are preteens between the ages of 10 and 12 years screened and offered a Tdap vaccine? 
Are adults screened and offered the Tdap booster immunization for protection of 
pertussis? Several family practice clinics in Mississippi were the setting, and the target 
population was preteens between the ages of 10 and 12 years and adults over the age of 
18 years. Fifty different charts from four different clinics were used for data collection. 
The analysis used to organize and interpret the data was frequency distribution, means, 
and standard deviation. 
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CHAPTER I 
Dimensions of the Problem 
Pertussis, commonly called whooping cough, is one of the leading causes of 
vaccine preventable deaths despite the availability of a safe immunization. An average of 
50 million cases occurs worldwide each year with 300,000 resolving in death. In the last 
10 years there has been an increase in pertussis-related deaths in infants. In mid-2011, 
preteens and adolescents had a sustained epidemic increase in the spread of Bordetella 
pertussis or whooping cough (Debolt, Tasslimi, Bardi, Leader, & Hiatt, 2012). Pertussis 
is a highly contagious respiratory disease that can be spread by coughing. The cough can 
last for months and cause serious health problems. As of October 2012, Washington, DC 
and 48 other states have seen an increase in reported pertussis outbreaks compared to the 
same time in 2011. A provisional count indicated 4,000 cases of pertussis have been 
reported to the Centers for Disease Control and Prevention (CDC) and 16 deaths in 2012. 
The majority of deaths occurred in infants under 3 months of age, children between the 
ages of 7 and 10 years, and adolescents between the ages of 13 and 14 years (CDC, 
2012b). According to the CDC, the tetanus, diphtheria, and pertussis (Tdap) vaccine is 
recommended for preteens between the ages of 10 and 12 years for protection against 
tetanus, diphtheria, and pertussis. Protection provided by the Tdap vaccine during 
childhood wanes and a booster Tdap shot are needed (CDC, 2012b). Receiving the 
booster not only protects preteens but also the people around them, especially infants and 
elders. When a majority of the community is immunized, the spread from person to 
person is less likely and is known as herd immunity. Newborns and people with chronic 
illnesses are offered some protection because the disease has less opportunity to spread. 
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This protection is important for infants not immunized, people immunocompromised, and 
people unable to receive vaccinations (Kennedy, Pruitt, Smith, & Garrell, 2011). There is 
a growing concern that as immunity wanes and others are not immunized there will be a 
considerable risk for outbreaks of pertussis. 
There is no cure for pertussis; the best offense is to protect the community from 
contracting and spreading the disease by vaccination. Children receive five doses of 
DTaP vaccine before they turn the age of 7 years: one vaccine at 2, 4, 6 months, one 
vaccine at 15-18 months, and one vaccine between 4 and 6 years of age. Once children 
become 10 years of age they are eligible for the Tdap booster vaccine, which contains 
lower levels of diphtheria and pertussis to decrease reactogenicity. Known side effects to 
the vaccine are injection site redness, swelling, nausea, vomiting, diarrhea, headache, 
fatigue, and myalgia. Children can have a Tdap booster vaccine as early as 7 years if 
they missed one of their five doses before the age of 7 years. It is recommended that 
adults 18 years and older should substitute a Tdap booster vaccine in place of a tetanus 
and diphtheria (TD) vaccine. Most recently, the Tdap vaccine as a booster shot to 
prevent pertussis has been approved for adults over the age of 65 years (CDC, 2012c). 
Problem Statement 
Pertussis was declared an epidemic in Washington State in April 2012. The CDC 
reported 2,520 cases by June 16, 2012, a 1300% increase from the same time in 2011 
(Debolt et al., 2012). The adult age group has been underdiagnosed with pertussis based 
on the fact that pertussis is under-recognized as a cough related issue (CDC, 2012c). The 
problem is preventing and controlling the spread of the disease to infants and others at 
greatest risk for severe disease because of waning immunity. The CDC has reported a 
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twofold to threefold increase in pertussis outbreaks in the state of Mississippi from 2011 
to 2012 (CDC, 2012b). 
Statement of Purpose 
The purpose of the study was to identify if preteens between the ages of 10 and 12 
years and adults 18 years and older are being adequately screened and given the pertussis 
booster vaccination Tdap to prevent the transmission of bacteria Bordetella pertussis. 
The researchers sought to discover if primary care providers are seeking pertussis 
immunization status and offering the patients the Tdap vaccine to prevent pertussis. 
Additionally, the researchers attempted to determine if educational material, such as the 
Vaccine Information Statement (VIS) for Tdap, was available for patients. Finally, 
researchers demonstrated the importance of recommending the Tdap vaccine to patients 
in targeted age groups. 
Significance of Research Project 
Parents miss an average of 44 days from work and experience a substantial 
economic burden because of the direct and indirect cost of pertussis. Children are seen in 
doctors' offices, emergency rooms, and hospitals with many missed days of school as a 
result of pertussis. The disease has the highest incidence of morbidity and mortality in 
infants because of decreased immunity from immature immune systems. Preventing the 
spread of disease in the infant age group by immunizing those individuals in close contact 
with the infant is considered cocooning. 
Mothers are given the immunization during pregnancy or during the postpartum 
period to protect the infants; however, more efforts are needed to immunize the entire 
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household (Casler et ah, 2012). The father, siblings, grandparents, and any immediate 
caregivers ideally should be vaccinated at least 2 weeks before contact with the infant. 
A missed opportunity to immunize on a day-to-day basis for adolescents and adults is a 
barrier which needs attention. A strong recommendation from a primary care provider 
has the most powerful influence on adults' decision to accept the vaccine. One way to 
become a more effective vaccinator is make an organizational change and have the office 
staff understand the importance of the immunization schedule. Every staff member needs 
to know the importance of immunizations; an assistant who answers the phone should not 
discourage patients from getting vaccines because of his or her own philosophy (Casler et 
al., 2012). Primary care providers have an increasingly difficult obstacle to overcome 
while trying to increase vaccination rates with adults. The lack of regular healthcare 
visits and lack of emphasis on documentations of adult immunizations are identified 
barriers that need to be addressed by the medical community (Casler et al., 2012). 
Theoretical Foundation 
Nola J. Pender's revised Health Promotion Model (HPM) was used for the 
framework of this study. Pender believes each person has a set of beliefs that can be 
inherited or acquired behavior. This behavior can result in the level of participation in 
self-health promoting behaviors. Actively endorsing immunization for patients is a 
means for the provider to increase the patient's commitment in health-promoting 
behaviors. A patient's experiences and beliefs can alter the perceptions of immunization 
to prevent pertussis. The researchers obtained vaccine information from select primary 
care offices in Mississippi. The goal was to identify if Tdap screening and 
immunizations were being provided to those in need of the vaccine. 
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Pender conducted research in 1978, in which she explored the behavioral 
characteristics of a community and the prediction of the community to use health 
promotion services when available if given by a nurse practitioner. More than 60% of 
people in the community would use the services if they were available. Using Pender's 
model in association with pertussis immunizations, a belief is formed in which health 
education of pertussis as a preventable disease through immunization would help the 
individual accept the vaccine based on his or her strong self-health promoting beliefs 
(Pender & Pender, 1980). 
Research Questions 
The following research questions were used for this study: 
1. Are adults 18 years and older being screened and offered the Tdap booster 
vaccination? 
2. Are preteens between the ages of 10 and 12 years being screened and offered the 
Tdap booster vaccine? 
3. Do primary care offices have and distribute education material about the Tdap 
immunization? 
Definitions of Terms 
The following are definitions of terms used in the study: 
Pertussis 
Conceptual: Known as a highly communicable disease caused by the bacteria 
Bordetella pertussis, causes paroxysmal or spasmodic coughing that usually ends in a 
prolonged, high-pitched, crowing inspiration, also known as whooping cough (Porter & 
Kaplan, 2011). 
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Operational: A vaccine preventable cough-related infection, which is reemerging 
because of w aning of the protection from childhood immunizations. The researchers are 
attempting to discover if the immunization for the infection is being giving to those who 
meet CDC age criteria. 
Diphtheria-Tetanus-Pertussis (Tdap) 
Conceptual. Diphtheria (D) vaccines contain toxoids prepared from 
Corynebacterium diphtheria. Tetanus (T) vaccines contain toxoids prepared from 
Clostridium tetan. Acellular (a) pertussis (P) vaccines contain semi-purified or purified 
components of Bordetella pertussis. There are two types given in the United States: 
DTaP given to children under the age of 7 years and Tdap for adolescents and adults. 
The Tdap contains lower doses of diphtheria and pertussis components (indicated by the 
lower case d and p) (Porter & Kaplan, 2011). 
Operational: The first vaccine for preteens, adolescents, and adults over the age 
of 65 years, which protects against pertussis as well as tetanus and diphtheria given as a 
booster shot. The immunization being studied should be given in primary care clinics to 
prevent pertussis. 
Preteen 
Conceptual: A human 10 through 12 years of age (Porter &Kaplan, 2011). 
Operational: The age group the CDC recommends receiving the first Tdap 
booster shot. 
Adult 
Conceptual: A human 18 years of age and older (Porter & Kaplan, 2011). 
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Operational. The age group the CDC recommends receiving a Tdap booster in 
place of a TD vaccine one time during adulthood. 
Primary Care Providers 
Conceptual. A healthcare professional who helps in identifying, preventing, and 
treating illness or disability (Porter & Kaplan, 2011). 
Operational: A healthcare professional (e.g., doctor, nurse practitioner, or 
physician assistant) that would screen, administer, and chart Tdap immunizations. 
Assumptions 
The researchers assumed primary care providers know the correct immunization 
schedules and when to administer the correct vaccination. The researchers assumed that 
each chart has adequate documentation of Tdap vaccine. 
Summary 
Cyclic increases in pertussis happen approximately every 4 to 5 years, which 
sometimes reaches epidemic proportions similar to the amount of outbreaks the United 
States has experienced this last year. Pertussis is also being underdiagnosed because it is 
not looked at as a differential diagnosis for a cough-related disease in preteens and 
adolescents. Primary care providers need to explore different strategies to increase 
immunization throughout the age span, such as (a) decreasing missed opportunities 
during day-to-day patient care interactions, (b) developing a more comprehensive way to 
keep track of adolescent and adult vaccination, and (c) educate the office staff on 
importance of the immunization. Dr. Audrey Stevenson, who coordinates family health 
related services for the Salt Lake Valley Health Department, stated that, "We still have 
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much to do in order to educate and vaccinate. None of us is as good as all of us" (Casler 
et al., 2012, p. 6). 
CHAPTER II 
Review of Literature 
The purpose of the study was to identify if preteens between the ages of 10 and 12 
years and adults 18 years and older are being adequately screened for the pertussis 
booster vaccination to prevent the transmission of the bacteria Bordetella pertussis. 
Bordetella pertussis is a bacterium that causes pertussis, also known as whooping cough. 
Pertussis is a highly contagious respiratory disease that can be fatal in infants and the 
elderly. According to the (CDC, 2012b), 27,550 cases of pertussis were reported in the 
United States in 2010. However, many cases of pertussis may go undiagnosed and 
unreported. The 27,550 cases of pertussis in 2010 is the highest reporting of pertussis 
since 1959 with a reported 40,000 cases. The spread of pertussis is prevalent and 
increasing in the United States with an estimated 300,000 deaths occurring worldwide 
each year. Pertussis is preventable and remains one of the leading causes of vaccine 
preventable deaths. The most effective way to prevent pertussis is to vaccinate children 
with the Tdap vaccine (CDC, 2012b). Since protection from the vaccination will lose 
effectiveness over time, preteens, adolescents, and adults need a Tdap booster (CDC, 
2012c). 
Literature reviews were conducted to obtain information regarding the 
appropriate screening and administration of Tdap in adolescents and adults with the 
hope to prevent the spread of pertussis. The research studies suggested that initial 
prevention begins with primary care providers (PCP) who play a vital role in the 
effectiveness of screening and treatment against pertussis. The review of literature 
supported the recommended guidelines of the CDC for screening and booster vaccine 
of all preteens between the ages of 7 and 12 years and adults over 65 years. The six 
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literature reviews provided the results of additional studies strongly related to the 
current study. The reviews provided information regarding theory, diagnostic tests, 
knowledge gap in primary care, and recommendations concerning the Tdap vaccine. 
Pender's theory is the framework used to guide the research on prevention of 
pertussis since the theory focuses on health promotion, illness prevention, and upholding 
well-being. Pender's Health Promotional Model theory has many key elements that 
address the influences of an individual's decision and behavior that lead to health-
promoting actions. The most relevant part of the Health Promotional Model is the 
variable of interpersonal influences. Interpersonal influences are the person's thoughts or 
beliefs about the behaviors, attitudes, and beliefs of others and may not accurately reflect 
those behaviors, attitudes, or beliefs (Pender, Murdaugh, & Parsons, 2006). An 
individual may be influenced from a variety of sources, such as family, peers, and 
healthcare providers. 
With the epidemic rise in the outbreak of pertussis, the responsibility of a 
healthcare provider is to be the main source of influence for the community and promote 
participation in prevention of further spread of the disease. The healthcare provider may 
use an array of various methods to encourage individuals to participate in the prevention 
of pertussis. The healthcare provider should participate in the necessary steps of 
screening, educating, and encouraging immunization within the community. Increasing 
an individual's knowledge, awareness, and detection of pertussis will allow a decrease in 
the spread of pertussis in communities and newborns—currently the population at highest 
risk for mortality with pertussis. Positively influencing a person's decision-making and 
actions could be as simple as providing accurate and educational information. When 
accurate information is provided, individuals can take part in their own care in prevention 
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of diseases and illnesses. Applying the Health Promotional Model will provide guidance 
in creating a supportive and high quality implementation plan, which leads to 
achievement of health-promoting behaviors. 
Review of Related Research: Diagnostic Test for Pertussis 
Hajia, Rahbar, Fallah, and Safadel (2012) revealed a diagnostic tool referred to 
as the PRC, which is a tool that accurately assists in screening for pertussis in 
individuals who may be difficult to diagnose. Hajia et al. (2012) conducted a 
quantitative research study. Using a systematic approach, the authors collected data 
with a numerical statistic technique to reflect the results of each participant's positive 
and negative test outcomes. Early signs and symptoms of pertussis are often 
nonspecific and difficult to determine in the early stages. Undiagnosed patients 
infected with pertussis have a high risk of transmitting the disease to others in the 
community (Hajia et al., 2012). The authors sought to discover a way to help improve 
laboratory diagnosis tests for pertussis and to distinguish which test is more sensitive 
and specific for detection of pertussis. The main diagnosis test researchers wanted to 
study was on Polymerase Chain Reaction (PCR). PCR is a molecular technique used 
to detect DNA sequences of the Bordetella pertussis bacterium and, unlike culture, 
does not require live bacteria present in the specimen (CDC, 2012a). 
Hajia et al. (2012) did not state a specific research question. To evaluate the 
frequency of Bordetella pertussis among received specimens, the authors stated the 
concern and necessary reasons for the conduction of research. The authors' purpose was 
to investigate several laboratory diagnostic tests that would prove to be more sensitive in 
diagnosing pertussis. 
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A cross-sectional study was the method used to conduct the research. A cross-
sectional study was appropriate for this type of study—observing the chosen population 
at a point in time. This type of study allows the authors to describe the prevalence of the 
pertussis and help validate the reliability of the test. The design method tested 93 males 
and 45 females for a total of 138 participants. All of the participants were under 6 
months of age and suspected of having whooping cough. The researchers used special 
swabs to collect specimen from the sample. The specimen was used in two tests—the 
ELISA and the Polymerase Chain Reaction. The tests, which resulted positive for 
Bordetella pertussis, were recorded in SPSS software and converted into percentage. The 
population in the study was children < 6 months old suspected of whooping cough. The 
participants' vaccination history was used to define the sample selection. Subjects were 
excluded if they have been vaccinated for pertussis. 
Data were collected using the diagnostic tests ELISA and PCR. In ELISA, a kit 
was used to detect Bordetella antigen containing pertussis toxin by applying enzyme 
linked immunosorbent assays to the commercial kit (Hajia et al., 2012). In PCR, a High 
Pure PCR Template preparation kit was used to perform DNA extraction to detect 
specific genome in the patients with pertussis (Hajia et al., 2012). The data were 
calculated by software called SPSS, which converted the results into a percentage. The 
data established how sensitive each test was to detect Bordetella pertussis in the 
population. The sample for the research was a nonrandom sample of the population. The 
sample that the researchers chose to conduct the study was on 6-month-olds suspected of 
having whooping cough and unvaccinated infants. 
The statistical method used to analyze the data was a specific type of software, 
SPSS software version 16. The SPSS software is a complex data collection analysis 
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procedure. A limitation of Hajia et al. (2012) was that the research did not thoroughly 
explain the method of data collection. The graph showed negative and positive controls 
of each participant; however, it did not explain specific reaction versus internal control. 
Hajia et al. also failed to explain the background sample or result. The findings 
concluded that the PCR method is verified to be sufficient, stable, and able to provide 
reproducibility of results when tested. The test reported a high sensitivity ratio. Hajia et 
al. (2012) stated that the testing for pertussis by PCR method is highly sensitive but 
recommended adding the ELISA testing to help eliminate any false positive with either 
test. 
In conclusion, Hajia et al. (2012) could have added more diverse participants to 
the study so the outcome of the findings could have been compared between two different 
populations to strengthen their study. Strengths of Hajia et al.'s study provided the nurse 
practitioner student with a better understanding regarding the various tests used to detect 
Bordetellapertussis. The research by Hajia et al. was very informative regarding the 
detailed steps of ELISA and PCR testing. Prior to the vaccination, the public was not 
aware of the infection. The study was conducted in Iran, which shows that pertussis is 
not only a problem in the United States. It is possible that in the near future that the U.S. 
along with other countries may be battling the spread of pertussis resulting in an epidemic 
problem. Knowing the significance of the problem will increase the eagerness of the 
public, healthcare providers, and researchers to strive to find a solution for the prevention 
against pertussis. 
Hajia et al. (2012) was valuable to the current research study as it emphasized the 
importance of appropriate screening to prevent pertussis. Diagnosing pertussis may be 
delayed in non-symptomatic patients or patients who do not present with the classic 
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symptoms of pertussis. The delay in diagnosing will cause an increase in transmission of 
the infection in the community. It is important to note that screening for the infection 
should not only be based on clinical signs and symptoms. Hajia et al. (2012) proved a 
positive outcome when utilizing PCR in screening for pertussis. Therefore, it was used in 
the current research project to facilitate the screening process for pertussis and support 
the diagnosis. 
Knowledge Gaps in Primary Care 
Gannon, Qaseem, Snooks, and Snow (2012) exposed the necessity of primary 
care providers (PCP) focusing on preventable healthcare needs at each visit. Increasing 
the knowledge base for PCPs will encourage them to recommend the booster vaccine to 
protect against pertussis. The purpose of Gannon et al.'s (2012) study was to improve the 
immunization practices in primary care settings using a team approach. Their study was 
a quantitative prospective study. The quality of care in the primary care setting lacked 
preventive care because the physician and office staff were focused on acute needs of the 
patients. The lack of quality in our nation's healthcare system has increased because our 
focus is on complex medical problems. The American College of Physicians (ACP) 
developed a quality improvement curriculum to encourage physicians and practice teams 
to learn about the current recommendations and practices for adult immunization. 
Childhood vaccinations have become a public health success and adult vaccination rates 
are not increasing, thereby prompting a change toward lifespan immunizations. Adults 
are the primary source of infectious transmission to unprotected infants (Texas 
Department of State Health Services, 2012). 
The authors evaluated the development of quality improvement teams in the 
primary care setting that will have an impact on adult immunization rates. The team 
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approach was developed and taught by two main faculty researchers to 20 primary care 
practices. Teams of four (a physician, nurse, front office staff, and a medical tech) were 
frequent combinations. The researchers used quality improvement methods to teach a 
team approach, thereby increasing knowledge, education, and administration of vaccines 
to adults. 
"The null hypothesis for this study was that the intervention would have no 
impact on the immunization rates of the practice after the intervention" (Gannon et al., 
2012). Seventeen of the 20 enrolled practices completed the study. The sample included 
the practice of randomly auditing 35 charts at two points in time—baseline and 12 
months later. The population included patients 18 years and older and those who had 
been under the clinic's care for more than one year. Data were collected for influenza, 
pneumococcal, tetanus diphtheria (Td)/Tetanus diphtheria pertussis (Tdap), hepatitis A, 
hepatitis B, meningococcal, varicella, herpes zoster, and human papilloma virus. During 
the two specific dates, the quality improvement teams were given access to online 
educational tools, feedback surveys, and conference calls coaching quality improvement. 
Patient chart abstraction data were collected twice during the study from two different 
sources. First, a physician practice pattern survey was used and secondly a patient chart 
abstraction form. The physician practice survey used a Likert-scale response and 
captured the beliefs of the physician practice using a team approach for the vaccination of 
adults in their practice. 
Patients' right protection was not mentioned. Gannon et al. (2012) did not avoid 
bias in sampling. Several biases were cited and considered limitations for the study. The 
statistical data methods were chi-square tests and analysis of variance tests. The p values 
of < .05 were considered statistically significant. The Td/Tdap rates went from 45.6% 
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pre-intervention to 55% post-intervention { p  < .01). Physicians made significant 
improvements with their immunization rates by discussing immunization with their 
patients and giving the immunizations themselves. The physicians also saw significant 
improvement by using the CDC immunization schedule. The practice teams were taught 
small steps and changes that would increase their success at sustained change. 
Gannon et al. (2012) recommended the information could encourage small clinics 
with paper-based practices to use this information and change their practices with 
minimal effort. The program encouraged the support team to give a small part of their 
autonomy to better serve the goals of the practice. The change in adult vaccination takes 
a team approach, which is invested in quality improvement. 
The current study specifically addressed whether adults and preteens between the 
ages of 11 and 12 years are being screened and given the Tdap vaccine in select practices 
in Mississippi. Gannon et al. (2012) estimated that 50,000 to 70,000 U.S. adults die each 
year from diseases that could be prevented by vaccination. However, quality gaps in 
healthcare and missed opportunities for screening for appropriate vaccination exist 
between those recommended to receive vaccination and those who received the 
vaccination (Gannon et al., 2012). Researchers try to improve adult immunizations with 
a quality care-based intervention, which focuses on a team approach in the primary care 
settings. The team-based approach worked well in this study; it can be generalized that 
the same approach would work well in Mississippi. Improving adult immunization will 
decrease the rate disease is spread in the United States, including Mississippi. 
Rossi-Foukes et al. (2010) disclosed that primary care providers' lack of 
knowledge has a huge impact on the prevention of pertussis. Rossi-Foukes et al. (2010) 
conducted a quantitative study using a methodical approach to collect data. Using a 
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numerical statistic structure for the collected data, the authors reflected accurately each 
participant's outcome to the research conducted. According to Rossi-Foukes et al, 
pertussis is underreported in the adolescent and adult populations with estimates as high 
as 1,000,000 cases among people aged 15-64 years annually in the United States. The 
researchers were completely aware of the existing studies documenting the underreported 
diagnosis of pertussis in adolescent and adult populations; however, the researchers did 
not identify documentations regarding physicians" knowledge of pertussis. Rossi-Foukes 
et al. (2010) were eager to conduct research to discover if the treatment of pertussis was 
dependent on the physician's knowledge concerning the highly communicable infectious 
disease. 
Rossi-Foukes et al. (2010)'s questions and hypothesis were clearly stated and 
their desire to conduct the research was evident. The researchers questioned if a 
physician's lack of knowledge of pertussis is the likely cause of ineffectively diagnosing 
and treating pertussis. The hypothesis was that there are significant gaps in knowledge 
regarding pertussis, particularly among non-pediatricians. Rossi-Foukes et al. believed 
that Board preparation materials were not sufficient to educate physicians about pertussis 
(2010). 
The independent sample t test and Mann-Whitney U test were the methods used 
to conduct the research on the physicians. The independent sample t test was used to 
compare the differences between pediatricians and non-pediatricians to determine if a 
significant difference in scores existed between the two groups. The scores were 
calculated by the percentage of correct answers based on a 12-question knowledge survey 
consisting of assessing the knowledge of pertussis in regard to the vaccines' immunity, 
transmission, reservoir, vaccination, treatment, diagnosis, and reporting requirements 
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(Rossi-Foukes et al., 2010). Upon completion of the independent t test, the Mann-
Whitney U test was used to meticulously compare the individual questions and subject 
performance between pediatricians and non-pediatricians (Rossi-Foukes et al., 2010). 
Rossi-Foukes et al. (2010) surveyed two neighboring counties in northern Illinois 
within two time periods. The first study was conducted from July 2002 through February' 
2003 in McHenry County, Illinois, based on a population of 296,389 residents. The 
second study was conducted from July 2003 through February 2004 in Kane County, 
Illinois, based on a population of 472, 482 residents. The samples were randomly 
selected to avoid bias. The criteria for selection required that the physicians be practicing 
and involved in patient care at least 20% of their time within the past year (Rossi-Foukes 
et al., 2010). The physicians were sampled as two groups, pediatricians and non-
pediatricians. The non-pediatricians group included a wide variety of internists, family, 
and emergency physicians. 
Rossi-Foukes et al. (2010) avoided bias sampling by using a list of physicians for 
each county provided by the local health departments. Within the provided list for Kane 
and McHenry counties, physicians were randomly selected. A total of 39 pediatricians, 
65 internists, 58 family medicine physicians, and 2 emergency medicine physicians were 
selected to participate in the survey. A total of 167 physicians were selected to 
participate in the survey which consisted of 39 pediatricians, 65 internists, 58 family 
medicine physicians, and 12 emergency physicians. Of the 167 physicians, only 33 
pediatricians, 31 internists, 32 family medicine, and 5 emergency physicians participated. 
A survey was sent to each participating physician via phone, mail, or fax. The accepted 
answers from the survey were measured as an average based on how the participants 
performed individually and as a group of either pediatrician or non-pediatrician. 
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Data from the survey were separated into two groups: pediatrician and non-
pediatrician. The answers from the two groups were analyzed and reviewed based on 
knowledge and correctness on each subject of the survey. An average was used for each 
topic. The results revealed that overall pediatricians scored higher than non-
pediatricians. The pediatricians also answered more accurately on 9 of the 12 knowledge 
questions except questions regarding reporting, transmission, and treatment (Rossi-
Foukes et al., 2010). Fifty-two physicians suspected pertussis on the survey; however, 
only 12 physicians reported the diagnosis to the health department. Many of the 
physicians who did not report the cases stated it was because of lack of positive 
laboratory confirmation. Researchers discovered that family practitioners were less 
likely than pediatricians to test for pertussis and less likely to diagnosis a patient with 
pertussis when presented with the standardized symptoms (Rossi-Foukes et al., 2010). 
Rossi-Foukes et al. (2010) believed that the knowledge deficit among non-
pediatrician on the awareness of pertussis derived early in medical training based on 
inadequate coverage of pertussis in medical school and residency curricula. Rossi-
Foukes et al. recommended a more comprehensive coverage of pertussis in early medical 
training along with a pediatric board preparation tool similar to those currently used by 
pediatricians. 
A limitation of Rossi-Foukes et al.'s (2010) study was that it did not cover 
precisely the format of the survey and the scale used to evaluate the answers. Rossi-
Foukes et al. provided valuable information to help prevent the spread of pertussis and 
concluded that prevention of the spread needs to be targeted on accurate diagnosis and 
reporting from the physician's standpoint. 
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Rossi-Foukes et al. (2010) was useful in the current research project to determine 
if healthcare providers are knowledgeable about proper screening and administration of 
the Tdap vaccine. A healthcare provider's role has a big impact on the awareness and 
detention of pertussis in adults and adolescents. Rossi-Foukes et al. highlighted a lack of 
knowledge among healthcare providers which leads to interference with reducing 
pertussis transmission in the community. A more effective method of prevention and 
treatment of pertussis will occur if the knowledge gaps are restored. Rossi-Foukes et al. 
(2010) provided baseline data quantifying pertussis knowledge among healthcare 
providers. 
Recommendations for Tdap Vaccine 
Based on a review of the literature, recommendations for the Tdap vaccine are as 
follows: 
The Advisory Committee on Immunization Practices (2006) examined the safety 
and effectiveness of the Tdap vaccine among preteen and adolescent age groups. 
Pertussis is a highly contagious infection affecting infants, preteens, adolescents, and 
adults. The tetanus toxoid, reduced diphtheria toxoid, and an acellular pertussis (Tdap) 
vaccine have been recommended by the Advisory Committee on Immunization (ACIP) 
(2006) and the (CDC, 2012b) as a way to protect adolescents and adults from acquiring 
and spreading the disease. In addition to pertussis, adolescents who live in crowded 
living conditions similar to college dorms are also at risk for acquiring N. Meningitis 
infection, which can cause meningitis. The tetravalent meningococcal polysaccharide 
protein conjugate (MCV4) vaccine has been shown to protect against meningitis. The 
Tdap vaccine was mandated for children entering the sixth grade in New York, but the 
MCV4 vaccine was an optional immunization. 
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A quantitative prospective cohort study was performed. The purpose of the study 
was to evaluate changes in Tdap and MCV4 coverage following the New York State 
requirement that a Tdap vaccine be given before entering the sixth grade. The data were 
collected using a hospital-based immunization registry measuring Tdap and MCV4 
coverage among adolescents between the ages of 12 and 14 years in New York City at 
three time points: pre-mandate, mandate year plus one, and mandate year two. 
The research questions for the study were as follows: Will a new mandate for the 
Tdap vaccine being given to sixth graders improve the Tdap vaccine coverage for sixth 
graders and for non-mandated age groups? Will the Tdap vaccine mandate increase non-
mandated, age-appropriate vaccines? 
Data were gathered over three distinct periods of time: (a) October 1, 2006-time 
pre-mandate, (b) October 1, 2007-the year of the mandate, (c) October 1, 2008-one year 
after mandate. EzVac, a web-based registry that consolidates immunization records for 
all clinics and hospitals apart of the New York-Presbyterian (NYP) hospital system, was 
used to collect data (ACIP, 2006). 
Among the patients who were Tdap eligible, the Tdap vaccine coverage increased 
from 29% premandate to 58% in mandate year one and 83% mandate year two for all age 
groups. The most notable increase was in age groups 11 and 12, but 13 and 14 increased 
in an acceptable percentage. The immunization coverage for the MVC4 increased in all 
age groups: premandate rates, 10%; mandate year one, 30%; and mandate year two, 60%. 
The effectiveness of a mandate to increase coverage of a vaccine was substantial, 
which is consistent with previous studies. In addition, coverage among other age groups 
not targeted increased. The goals in increasing immunization to reduce pertussis 
transmission were laudable, but reliance on school mandates is a cause for concern. The 
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mandates put stress on already overburdened school systems, and mandates can cause 
parents to experience distrust. The MCV4 non-mandated vaccine administration rates 
increased, and teaching provider to screen for all vaccines instead of just-mandated 
vaccines most likely attributed to this increase. 
Weston, Friedland, Wu, and Howe (2011) examined the safety and effectiveness 
of the Tdap vaccine among the elderly. Weston et al. (2011) conducted a quantitative 
study. The authors identified variables and collected data in a numeric form. Research 
has validated that immunity against pertussis diminishes as an adult ages despite 
receiving a TDAP vaccination as an infant. In 2005, the CDC (2005) recommended 
individuals between the ages of 11 and 65 years should receive a booster vaccination to 
prevent pertussis. The (CDC, 2012c) also advised adults < 64 years old to receive a 
booster vaccination for pertussis if close contact to infants < 2 months of age is frequent 
(Weston et al., 2011). However, the Tdap vaccination for adults > 65 was not 
recommended due to the lack of safety and immunogenicity data of Tdap use in this age 
group (Weston et al., 2011). Weston et al. sought to discover the safety and 
immunogenicity data for adults < 65 receiving the Tdap vaccination. Weston et al. also 
wanted to identify if there really are risks for adults > 65 years. 
Weston et al. (2011) found further research in 2008 revealed that the high 
incidence of pertussis significantly increased in adults > 65 years. The researchers 
clearly stated that adults > 65 years should receive the Tdap vaccination. Weston et al. 
declared that vaccinations provided two valuable benefits. Two of the benefits included 
prevention of an individual from contracting the disease and prevention of the infected 
individuals from exposing the disease to other high-risk candidates such as infants. 
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Weston et al. (2011) conducted two studies to test the safety and immunogenicity 
of Tdap. In Study A, subjects received a single dose of Tdap along with a flu vaccine 
either administered at the same time or given one month apart (Weston et al., 2011). In 
Study B, participants received either the Tdap or Td vaccine. To ensure accuracy of 
results, antibodies were measured precisely prior to vaccination and one month post-
vaccination. 
To protect the rights of each individual, a signed written consent was required 
prior to the study. The subjects' rights were protected by the principles of Good Clinical 
Practice and the Declaration Helsinki. The study consisted of data collection over two 
separate time periods. Study A was conducted in 12 centers in the United States between 
October 2006 and February 2007. Study B was conducted in 24 centers in the United 
States between February 2009 and October 2009. To participate in the study, the subjects 
had not received the Td booster within the last 5 years, had a history of diphtheria, 
tetanus or pertussis disease, and had not received an influenza vaccine within 6 months of 
the study (Weston et al., 2011). The qualified subjects were then placed into two groups 
for Study A and Study B. A total of 217 subjects received the Tdap vaccination along 
with the flu vaccination in Study A, and 887 subjects received either the Tdap or Td 
vaccination in Study B. A total of 1,104 subjects participated in the two studies. 
Blood samples were taken from each subject prior to initial vaccination and one 
month after each subject received vaccination. The vaccine was administered 
intramuscularly into the deltoid in the non-dominant arm. For Study A, researchers used 
the enzyme linked immunosorbent assays to measure antibodies against D, T, and 
pertussis antigens. A booster response was defined as a post-vaccination antibody 
concentration of > 20 El/ml in initially seronegative adults and an increase in the post-
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vaccination concentration of > 4 times the pre-vaccination antibody concentration in 
subjects with pre-vaccination antibody concentrations between 5.0 El/ml and > 20El/ml 
(Weston et al., 2011). In Study B, the subjects were instructed to document any adverse 
side effects experienced after receiving the vaccination during the 4-day follow-up period 
on a diary card. For Study A, the follow-up period for solicited adverse events was 15 
(Weston et al., 2011). Subjects were to document any experience of local and general 
adverse effects. Local adverse effects included pain, redness, and swelling at the 
injection site. General adverse effects included fever, fatigue, gastrointestinal symptoms, 
pain, muscle pain, shivering, and headache (Weston et al., 2011). The researchers used a 
scale of 0-3 to grade each adverse effect experienced by the participants. 
The researchers analyzed their data with a statistical analysis computing an 
average. In Study A, computer software SAS and Proc Statx act 5.0 were used. In Study 
B, Drug Development version 3.5 and Statxact-8 procedure were used to obtain statistical 
analysis results. The analysis of safety was performed on the total vaccinated cohorts, 
which included all subjects who had received at least one vaccine dose (Weston et al., 
2011). The subjects were grouped according to the vaccine received for the analysis. 
Study A concluded a difference in immune response to Tdap or influenza vaccine 
observed between co administered or sequentially administered vaccines did not exist 
(Weston et al., 2011). Study B showed adverse reaction ranging from generally mild to 
moderate in intensity (Weston et al., 2011). Based on results of the study, it is safe to 
administer the Tdap vaccine with or without the influenza vaccine to adults > 65 years. 
The study also showed when the Tdap is administered to adults 65 years or older there is 
immunogenicity present where the adult could provoke an immune response to protect 
against pertussis. Weston et al. (2011) recommended providing pertussis vaccination to 
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adults > 65 years. The elders have been associated as transmitters of pertussis disease to 
young infants and children. Administering vaccination to elders would help prevent 
pertussis-associated morbidity in the elderly population and decrease transmitting of 
pertussis to vulnerable infants and young children (Weston et al., 2011). Weston et al.'s 
study cited two distinctive studies confirming the safety of vaccination and 
acknowledgement of an affirmative change in the body when vaccinating adults > 65 
years. 
The current research study addressed whether or not adolescents and adults are 
being screened and administered the Tdap vaccine. Weston et al. (2011) was useful to 
the current study because it provided knowledgeable information about the safety and 
importance of Tdap immunization in adults > 65 years. The incidence of pertussis in the 
United States has increased yearly, with the greatest rate of increase observed in adults > 
65 years (Weston et al., 2011). Weston et al. concluded that increasing age does not 
provide immunity against disease; hence, immunization is essential. Based on the results 
of Weston et al., the current researchers included adolescents and adults which allowed 
proper screening throughout the age span. 
Carstensen et al. (2012) examined the safety and reaction of the Tdap vaccine 
administered to healthy adults. The purpose of Carstensen et al. (2012) was to obtain 
clinical documentation of the safety and immunogenicity of the Tdap vaccine when given 
to healthy adults. Carstensen et al.'s study was a double-blind, non-inferiority clinical 
trial. The relevance increased the knowledge base for PCPs and encouraged them to 
recommend the vaccine as a booster to protect against whooping cough (Carstensen et al., 
2012). 
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Pertussis remains one the leading causes of vaccine preventable deaths with an 
estimated 300,000 deaths occurring worldwide every year. The ACIP recommends that 
all adults > 18 years receive a Tdap vaccine as a booster in lieu of the Td vaccine to 
protect against pertussis. The recommendation has indicated the relevance of the safety 
of the Tdap versus the Td (Carstensen et al., 2012). 
Several questions related to Carstensen et al.'s study were answered after the 
complete population was immunized with one of the two vaccines. Vaccination reactions 
were first studied. For the first 72 hours, did the patient have any injection site pain, 
swelling, or erythema? Did the patients have any headaches, fatigue, or myalgia? After, 
28-35 days, did the seroprotection rates increase in both Tdap and Td for tetanus and 
diphtheria and was the seroprotection increased for pertussis in the Tdap sample 
(Carstensen et al., 2012) 
The method of a double-blind, randomized, controlled trial was used for the 
study. The patients' blood samples were drawn before the immunizations were given and 
one month after the immunizations for serological analysis and adverse events were 
recorded during the month after injections were received. Prior to initiation of the trial, 
researchers went before their ethics committee and approval was obtained per protocol. 
The trial was conducted in accordance with the Declaration of Helsinki 59th WMA 
General Assembly in Seoul and was registered per protocol under clinical trials 
(Carstensen et al., 2012). 
The data were gathered at initiation of the trial and one month later. The target 
population consisted of 800 healthy female and male adults over the age of 18 years who 
had completed primary vaccination with Tdap in Denmark. Vaccinations were confirmed 
per vaccination card. In addition to the protocol, the trial required that at least 25% of 
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subjects be over the age of 30 years and 10% be over the age of 40 years. The main bias 
or exclusions criteria were subjects with immune deficiency, progressive neurological 
disease, uncontrolled epilepsy, and progressive encephalopathy. The data were collected 
at two trial visits. First, a pre-vaccination blood sample was drawn and the subjects were 
vaccinated with either Tdap or Td. Secondly, 28-35 days later a post-vaccination blood 
sample was drawn, and adverse events and concomitant medications were recorded. It 
was impossible to identify which vaccine was given to each patient (Carstensen et al., 
2012). 
The statistical methods were computed via the SAS POWER procedure 
(SAS/STAT9.2), and a Wilson method was used without a continuity correction. The 
Tdap vaccine was found to be safe immunogenically and non-inferior to the Td vaccine 
when given as a booster vaccination to adults. The safety and immunogenicity of the 
Tdap vaccine had already been established in children and adolescent populations. 
Carstensen et al.'s (2012) study supports vaccination in the adult population. 
The implications of Carstensen et al.'s study can be helpful to direct the focus of 
the current study. Focus of the current study was to determine if adolescents between the 
ages of 10 and 11 years and adults over the age of 18 years are being screened and 
offered the Tdap vaccination as a booster immunization. Knowledge of the 
immunogenicity and adverse reactions of the Tdap compared to the Td vaccine will 
provide information needed by PCPs who are still only giving Td vaccines. PCPs need to 
give Tdap vaccines in order to increase herd immunity of the pertussis disease. 
Summary 
The six literature reviews, along with Pender's theory of Health Promotion 
Model, provided valuable information and framework for the importance of the current 
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study. The literature review provided results of other studies that are strongly related to 
the current study. The reviews provided information regarding diagnostic tests, 
knowledge gap in primary care, and recommendations concerning the Tdap vaccine. The 
literature reviews increased the current researchers" knowledge base concerning pertussis 
and assisted in accurately collecting data for the study. 
CHAPTER III 
Methodology 
A quantitative chart review was conducted to evaluate if healthcare providers 
are screening, recommending, and administering the Tdap vaccine to eligible patients, 
particularly preteens between the ages of 10 and 12 years and adults 18 years and 
older. A quantitative, retrospective chart review was used to review 200 charts from 
four different clinics. This chapter identifies the setting, sample, implementation, and 
data analysis used for the study. 
Setting for the Research Study 
The setting for the research study was four primary care clinics: 2 specialized 
in pediatric patients for ages 10 to 12 years and 2 internal medicine clinics for patients 
18 years and older. Each of the four clinics in different regions of Mississippi 
provides a diversity of results. A pediatric clinic and internal medicine clinic from 
southwest Mississippi and a pediatric and internal medicine clinic from northwest 
Mississippi were sites used. 
Sample 
The population for this research study included patients receiving care at the 
pediatric and internal medicine clinics from January 2013 to March 2013. From each 
clinic, 50 charts were randomly selected for a total of 200 charts. The chart chosen had 
to fit in a set criterion. The criteria consisted of males and females between the ages of 
10 and 12 years and 18 years and older who visited the clinic for any reason. The 
criterion for this research study was based on the recommendations of Tdap vaccination 
from the CDC in regard to children ages 7 through 12 years and certain adults ages 18 
years and older. 
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Implementation of the Project 
Approval to conduct the study was obtained from Mississippi University for 
Women Graduate Program and IRB (see Appendix A). Research data were gathered 
using two clinical sites in southwest Mississippi and two clinical sites in northeast 
Mississippi. Written consent was obtained from each participating clinic (see Appendix 
B). Each researcher selected 50 charts from each site, and both researchers collected 50 
charts with dates of birth between 2001 and 2003 and 50 charts with dates of birth pre-
1995. This retrospective chart review followed HIPPA guidelines, did not use any 
human participants, and maintained confidentiality at all times to protect information 
gathered. Researchers collected data using a researcher-designed data collection tool (see 
Appendix C). Questions for the tool were identified by review of literature based on 
CDC guidelines for the Tdap vaccine. Numbers were used to prevent a break in 
confidentiality. Collected data were stored onto a portable disc drive, which only the 
researchers had access. The drive was kept secure and locked throughout the project. 
After research was completed, all stored data were destroyed. The researchers examined 
each chart to evaluate whether or not screening and administration of the Tdap vaccine 
had been administered. The data established if primary care providers were screening, 
recommending, and administering the Tdap vaccination. 
Data Analysis 
In the current research project, descriptive statistics were used to collect data. 
The data were analyzed using medians, means, modes, and percentiles. A t test was used 
to compare results from each clinic to see if there were any significant differences. 
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Summary 
The researchers utilized a retrospective, quantitative chart review. Each 
researcher collected data from 100 charts in the targeted age groups, 50 pediatric charts 
and 50 internal medicine charts. Based on data collected, the researchers could determine 
the consistency of screening and administering the Tdap vaccine at four different clinical 
sites in Mississippi. In addition, availability of Tdap vaccine education sheets were 
assessed at all sites to determine if the education sheets increased the vaccine rate. 
CHAPTER IV 
Presentation of the Findings 
The purpose of this study was to evaluate primary care providers' attention in 
screening patients for pertussis in certain high-risk age groups. The researchers also 
evaluated whether Tdap was administered appropriately to those individuals to prevent 
the spread of an outbreak. The researchers reviewed the charts of patients who were 
between the ages of 10 and 12 years and 18 years and older. This chapter presents a 
description of the researchers' sample of study, demographics, and analysis of the data 
collected. 
Description of the Sample 
Demographics that were examined in the study included gender and certain age 
groups. A total of 200 charts were reviewed. Gender was almost exactly the same (see 
Figure 1). Of the 200 subjects, the majority were between the ages of 10 and 12 and 18 
to 91 years old. In the adult age group, 53% (n = 100) represented the total participants 
that were screened and 47% were not screened. Out of 100 adult participants, 21% were 
given the Tdap booster vaccine, and 79% were not given the vaccine. In the pediatric age 
group, 78% (n = 100) represented the total participants that were screened and 22% of 
total pediatric participants who were not screened. Out of the 100 pediatric participants, 

















Patient Screened Vaccine Given 
Figure 1: Representation of gender related to study sample (N = 200). 
Research Questions 
Research question 1. Are adults 18 years and older being screened and offered 
the Tdap booster vaccination? According to the data analysis, 53.00% of adult patients 
are being screened, and 21.00% of adult patients are being given the Tdap booster 
vaccine (see Figures 2 and 3). 
Research question 2. Are preteens between the ages of 10 and 12 years being 
screened and offered the Tdap booster vaccine? The results of the study revealed that 
78% of pediatric patients are being screened, and 64% of pediatric patients are being 




53% Adults Screened 
Adults Not Screened 
Figure 2: Representation of adult patients screened or not screened for Tdap vaccine (n 
= 100). 
Adult Tdap Vaccine 
21% 
79% - Tdap Given 
Tdap Not Given 
Figure 3: Representation of adult patients given Tdap vaccine (n = 100). 
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Pediatric Screening 
• Pediatric Screened 
Pediatric Not Screened 
Figure 4: Representation of pediatric patients screened or not screened for Tdap vaccine 
(« = 100). 
Pediatric Tdap Vaccine 
m Tdap Given 
Tdap Not Given 
Figure 5: Representation of pediatric patients given the Tdap vaccine (n = 100). 
Research question 3. Do primary care offices have and distribute education 
material about the Tdap immunization? Of the four offices where the populations were 
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studied, 100% (N — 200) of the offices had educational material about the Tdap 
immunization (see Figure 6). The occurrences of the educational material given out were 
statistically significantly higher tor participants who had received a Tdap vaccination 
when compared to those who had not received a Tdap vaccination. 







Tdap Educational Material 
Yes No 
Figure 6.  Representation of educational material for Tdap vaccination in the clinics (tV = 
200). 
Additional Findings 
It should be noted that the differences in screening occurrence rates are 
stat istically significantly different between age groups, x~0> 200) — 13.829,p < .001, 
with pediatric patients being screened more than adult patients. The differences in 
vaccine delivery rates were also statistically significantly different between age groups, 
X2(l. 200) = 37.831./? < .001, with pediatric patients being given the Tdap booster 
vaccine more often than adult patients. 
There was no significant difference in screening rates, x2(l, 200) = 0.118,/? = 
.731, or vaccination administration rates, x;2(l, 200) = 0.700, /? = .403, based on patient 
gender. There were also significant differences in the data based on which location the 
researcher s analyst collected the data. Patients evaluated in the northeast Mississippi 
had a significantly higher rate of screening, jftl, 200) = 24.096,/? < .001, and a 
significantly lower rate of vaccination, x2(l, 200) = 3.458,/? = .063, compared to the 
patients evaluated in south Mississippi (see Table 1). 
Screening for Pertussis and Tdap Vaccine Given Based on Gender, Age, and Location 





































In the retrospective chart review, the researchers attempted to identify whether 
primary care providers were screening patients to prevent further outbreak of pertussis. 
A review of 200 charts was performed and the data were analyzed. Data were first 
compiled in Microsoft Excel. Data were collected from 200 clients (100 male and 100 
female). Adult patients ranged in age from 19 to 91 years 55.07, SD = 16.61). 
Pediatric patients ranged in age from ranging in age from 10 to 12 years (M = 10.97, SD 
= 0.81). Subsequent analyses were performed using Minitab statistical software, version 
16. Of the subjects studied, overall 65.50 % of patients were screened and 42.50% were 
given the Tdap booster. 
CHAPTER V 
The Outcomes 
The purpose of this research project was to determine if healthcare providers in 
Mississippi were screening and administering the Tdap to appropriate patients. Pertussis 
was declared an epidemic in Washington State in April 2012. According to the CDC, 
2,520 cases were reported by June 16, 2012, a 1300% increase from the same time in 
2011 (Debolt et al., 2012). The adult age group has been underdiagnosed with pertussis 
because of under-recognition of pertussis as a cough-related issue (CDC, 2012b). The 
problem is preventing and controlling the spread of the disease to infants and others at 
greatest risk for severe disease because of waning immunity. The CDC has reported a 
two- to threefold increase in pertussis outbreaks in the state of Mississippi from 2011 to 
2012. 
For the purpose of the study, the following questions were established to evaluate 
primary care provider attentiveness in preventing the outbreaks of pertussis: 
1. Are adults 18 years and older being screened and offered the Tdap booster 
vaccination? 
2. Are preteens between the ages of 10 and 12 years being screened and offered 
the Tdap booster vaccine? 
3. Do primary care offices have and distribute education material about the Tdap 
immunization? 
The sample for the study consisted of 200 charts collected from two adult and two 
pediatric primary care clinics in the state of Mississippi. Two of the clinics were from 
the northern area while the other two were from the southern area of Mississippi. In the 
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pediatric clinic, the charts were chosen based on the ages of 10 to 12 years. In the adult 
clinic, the charts were chosen based on 18 years and older. The data were collected using 
a data collection tool created by the researchers. The data were analyzed and compiled as 
percentages using descriptive statistics. 
Interpretation of Findings 
The researchers identified that the majority of males and females between the 
ages of 10 and 12 years were being offered or given the Tdap booster vaccine in this 
particular sample. The researchers believed that the administration of Tdap booster 
vaccine was higher in this age group due to the effect of the new Tdap guidelines. At the 
beginning of the 2012-2013 school year, all students entering public school systems in 
the state of Mississippi were required to have a Tdap vaccine prior to the start of school 
(CDC, 2012b). However, the adults in the primary care demonstrated that 53% were 
being screened, yet only 21% were vaccinated. The researchers believe that the reason 
for the difference in Tdap vaccine rates in adults is due to the need for education. The 
challenge would be educating the middle-aged and elderly adults about the benefits of the 
vaccine, its effectiveness, and its safety. 
The researchers reviewed several literature studies pertinent to the research study. 
This literature review aided in providing background and suggestion in the technique the 
research was done. Hajia et al. (2012) revealed diagnostic tools that can accurately assist 
in screening for pertussis in individuals who are difficult to diagnose. These researchers 
used the Polymerase Chain Reaction (PCR). The findings concluded that the PCR 
method is verified to be sufficient, stable, and able to provide reproducibility of results 
when tested. Hajia et al.'s study was informative; however, these researchers were 
41 
unable to use the study in the current research. The study took place in a primary care 
setting and the diagnostic tool and technique mentioned in Hajia et al. (2012) are not a 
common procedure used in screening for pertussis. 
Rossi-Foukes et al. s (2010) study revealed the lack of knowledge by healthcare 
providers in regard to diagnosing and preventing the spread of pertussis. This study 
aided in determining that healthcare providers' knowledge has a big impact on the 
awareness and detention of pertussis in adolescent and adults. The study also stressed 
that effective methods of prevention and treatment of pertussis will occur if the 
knowledge gaps are restored. The findings of this study validate what the current studies 
have shown—that education is vital in improving vaccine rates. 
Weston et al. (2011) indicated that the Tdap vaccine was safe and effective among 
the elderly. Weston et al. acknowledged that vaccinations provided two valuable 
benefits: (a) preventing an individual from contracting the disease and (b) preventing the 
infected individual from exposing the disease to other high-risk candidates such as 
infants. Weston et al. indicated a tremendous need to vaccine once the immunity of 
pertussis has diminished after 10 years. The study also supported the recommended 
guidelines of the CDC for screening and booster vaccine of all preteens between the ages 
of 7 and 12 years and adults 65 years and older. Weston et al. (2011) gave the 
researchers guidelines and confirmation that screening and immunization are vital in 
adults, especially adults 65 years and older. 
The priority for the primary care provider to screen adult patients at every visit 
was studied by Gannon et al. (2012). The study focused on the lack of preventive health 
care in the family practice setting because of the focus on complex medical problems. 
Gannon et al. developed a quality improvement curriculum and included all office staff 
members in the education of adult vaccine recommendations. The team approach 
increased the amount of adult vaccines given because each person in the office had the 
responsibility of screening patients. Gannon et al. (2012) encourage clinics in their area 
to use a quality team approach to improve the vaccination rates within their office setting. 
Requirement of a Tdap vaccine before entering the sixth grade improved 
vaccination rates in 11- to 14-year-olds in New York State. Kharbanda et al. (2010) 
found that a mandate on the Tdap vaccine before interring the sixth grade increased the 
vaccination rates in preteens and adolescents 11 to 14 years old. The results from this 
study are important because Mississippi has enacted a similar mandate, which requires 
that all children have a Tdap vaccine before entering the seventh grade. The current 
researchers confirmed that the pediatric population is being screened and given the Tdap 
vaccination more than adults but revealed the need to improve adult immunizations. The 
nurse practitioner could be a catalyst in improving adult vaccinations by educating their 
office workers and their patients. 
Carstensen et al. (2012) documented the safety and immunogenicity of the Tdap 
vaccine when given to healthy adults. Since the ACIP recommends all adults 18 years 
and older receive a Tdap booster once in place of a Td immunization to protect against 
pertussis (ACIP, 2006). Establishment of the safety of the vaccine will give the nurse 
practitioner an education tool to teach patients the importance of the vaccine. The study 
complements the current study because these researchers can use the knowledge to 
increase knowledge of other providers on the safety of the vaccine. 
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The nurse practitioner can use all the information from the researchers' study and 
the rev ievv of literature to increase their knowledge and practice skills on vaccination 
schedules for preteens, adolescents, and adults. Nurse practitioners can have vaccination 
information programmed into the electronic medical records at their offices to increase 
compliance with screening and giving vaccinations. 
Limitations 
Limitations identified in the study that could have affected the outcomes were as 
follows. First, the sample collected was small in size. Only 200 charts were used in the 
study, which is a small number and may have significantly decreased the reliability of the 
results. Second, one of the clinics evaluated did not have a system for charting 
recommendations or education on Tdap. Some patients may have received the 
recommendation to receive the Tdap booster, but the information may not have been 
documented in the chart. 
Implications and Recommendations 
There are a few implications for future research in the area of the Tdap vaccine. 
It would be interesting to see if the Tdap vaccine rate decreases after the new regulation 
that Medicaid will not cover the cost of the vaccine. Another area for future research 
would be a study using a larger and more diverse population. Increasing the sample size 
and expanding the geographical area for data collection would result in a more thorough 
and accurate result. The influence of this study on the researchers has increased their 
interest in vaccine administration and education. 
The researchers" recommendation for this study is to urge primary care providers 
to promote more education about the need for the Tdap vaccine to he repeated. Providers 
might consider building a reminder into the electronic medical record program to ask 
patients about the Tdap vaccine. This approach would give healthcare providers the 
opportunity to educate the patient about the Tdap booster. The providers could also 
possibly educate the community by contacting the wellness center director about 
organizing groups, presenting talks, and sharing information pamphlets. 
Contribution to Nursing Theory 
The nursing theory used in this research study was Nola Pender's Health 
Promotional Model. Pender's theory implies that one behavior can result in the level of 
participation in self-health promoting behaviors. This theory is important to the current 
research study because with self-health promoting beliefs, such as the Tdap vaccine, 
pertussis can be prevented. This theory bases its importance on the patient's knowledge, 
experience, and beliefs in order to participate in health-promoting behaviors effectively. 
Actively endorsing Pender's theory of health promotion by educating and offering 
immunization is a means to increase the patient's behavior of illness prevention. After 
applying this theory to the research, it was clear that healthcare providers are the main 
foundation in promoting and providing prevention against life-threatening diseases such 
as pertussis. 
Conclusions 
The results suggest that healthcare providers in Mississippi are fairly consistently 
recommending and administering the Tdap vaccine to eligible pediatric males and 
females. However, there is a need for improvement in the adult population. The primary 
adult group that would benefit from being vaccinated was not based on lack of education 
on prevention regarding the importance of the Tdap booster vaccine. 
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APPENDIX A 
Approval of Mississippi University for Women 
Institutional Review Board 
Following is a summary of documents needed for use in the review. 
Form A- Identification of Investigators and Brief Review of Proposed Research 
(submitted by the researcher) 
Form B- Evaluation Form for Committee Review (submitted by the researcher) 
Form C- Sample of Informed Consent (submitted by the researcher) 
Form D- Guidelines for the Protection of Human Rights (used by the Review Panel) 
Form E- Definition of Terms (given to the researcher) 
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FORM A 
MISSISSIPPI UNIVERSITY FOR WOMEN 
INSTITUTIONAL REVIEW BOARD 
IDENTIFICATION OF INVESTIGATORS AND BRIEF DESCRIPTION OF 
INVESTIGATORS AND BRIEF DESCRIPTION OF 
PROPOSED RESEARCH REVIEW 
TITLE OF STUDY: 
Tdap screening and pertussis prevention throughout the age span 
PRINCIPAL 
INVES TIGATOR: Fhu Tran RN BSN. Cara Harris RN BSN 
(Signature) 
DEPARTMENT (Date)_ 
RESEARCH ADVISOR: Dr. Patsy Smvth 
(Signature) 
Instructions: In the space below (use additional sheets where necessary): 
1. Briefly describe the purpose and nature of the present research proposal. State what, if 
any. benefit is to be gained by the subject(s) or what information is to be added to the 
general body of knowledge as a result of this research. 
The purpose of the project is to determine if healthcare providers are recommending or 
administering diphtheria toxoid and acelluar pertussis (Tdap) to people ages 10-12 and 18 and 
older. Pertussis is a contagious disease, which has seen a substantial rise in epidemic 
proportions during 201 1. The diphtheria toxoid and acelluar pertussis (Tdap) vaccine is the 
most effective protection strategy for preventing the disease. 
2. List all procedures to be used on human subjects with a description of those Y O U  
consider beyond already established and accepted techniques. 
The research project is based on a retrospective chart review by the researcheis. therefore 
human subjects will not be tested or experimented on. onh used to obtain information in the 
study. 
3. Describe the necessary safeguards to be applied to protect the subject. 
The information obtained will not include anvjdentifiable characteristics such as names of the 
subjects from .hp chart review The only information that will be used will be the subjects' 
atte. race. and soy There wil' he nn nhvsical contact svith the patient, parent, or guardian. f the 
information obtained. Variables will be used on the data collection worksheet to 
represent the patients' age, race, gender; what type of healthcare provder was used 
1 medical doctor or nurse practitioner); and what type of insurance was used supjfe 
is a retrospective chart review. A_DataCoilection Instrument wtll be used to keep track of the 
- g — ^ ^ ^ T S U S S n U ^ T U u a r d . a n .  s . n c e  t h t s  , s  u t f o n u a t t o n  w t l l  
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be entered into a computer for statistical analysis. Collected data will be stored onto a portable 
flash drive, which only the researchers and researcher advisor could access by a password. 
The data collection worksheet will be shredded once the information has been saved onto the 
flash drive. The drive will be kept secure, and lock throughout the project. After research is 
complete and paper written with approval all stored data will be destroyed. 
4. State whether or not you consider the subject to be "at risk." If you consider the subject 
to be "at risk", in what respect do the potential benefits to the subject or contributions to the 
general body of knowledge outweigh the risks? 
Not applicable. 
5. If you consider the subject to be "at risk," state exactly what you tell him in lay 
language to obtain informed consent relative to each procedure wherein he is "at risk." 
This must be a form that is given or read to the subject particularly for this purpose. If 
subjects are children what will be told to parent or legal guardian? 
Not applicable. 
6. State from whom documentation of informed consent will be obtained. 
We plan to obtain consent from the two clinics the chart reviews will take place in Northeast 
and Southwest Mississippi. 
7. Attach copies of all questionnaires to be used. 
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FORM B 
EVALUATION FORM FOR 
INSTITUTIONAL REVIEW BOARD 
Date Submitted to Committee: 
Title of lnvestigation_Tdap screening and pertussis prevention throughout the age span 
Principal Investigator: Thu Tran; RN BSN, Cara Harris RN BSN 
Funding Agency. Funding is not necessary for this research project 
Funding Agency Grant 
Number: (N1H. BEH. when applicable): Anticipated number of 
human subjects to be studied (when applicable): Not applicable 
Projected duration of investigation: January 14. 2013-July 31. 2013 
Age range of human subjects: The retrospective chart review will be on subjects 11 to 65 years of 
age 
Any mental or physical impairment present in the subjects: The retrospective chart review will 
not include any known people with mental or physical impairments. We are not interviewing or 
having any physical contact with the participants. 
Criteria for subject selection . Preteens of the age of 11 and adults age 65 years and older. 
Potential for beneficial effect to human subject arising from investigation: The human subjects 
will not directly receive benefit from the research since the information will be obtained from a 
chart review 
Potential adverse effects (psychological, behavioral and physiological) arising from 
investigation: Since the information will be obtained from chart reviews, the subjects will not be 
inflicted with psy chological, behavioral, and physiological effects of the protect 
Potential or established side effects of drugs used in investigation! Since this is a retrospective 
chart review, there will not be drugs involved in the investigation 
Brief justification of research where immediate benefit to specific human subject is 
absent or unknown- Sinn, this is a retrospective chart review, specific human sublets mvolved in 
the study will not ^ive *nv benefits. The inMmatjmoMained during the research pro)ect mav 
help those in the future. 
For On-Going Investigations Only. Number of subjects studied: 200 chart reviews will be audited 
from 1 Northeast and 1 Southwest Mississippi clinics 
Documented adverse psychological, behavioral, physiological and pharmacological 
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eflects of stud} . I his is a retrospective chart review, therefore psychological, behavioral. 
physiological, and pharmacological effects will not be endured bv the participants 
Precautions used to detect, prevent, minimize or reverse adverse side effects * 
No precautions were utilized, since this was a retrospective chart review 
Change in methods or procedures (when applicable): 
Not applicable 




SAMPLE OF INFORMED CONSENT 
INSTITUTIONAL REVIEW BOARD 
1.State exactly what you will tell subject, parent/guardian. 
This is a retrospective chart review. We will obtain consent from 2 Mississippi clinics to obtain 
the information in the research project. 
2. State how you will obtain documentation of informed consent. (Submit sample 
document). See appendices 
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FORM D 
GUIDELINES FOR THE PROTECTION OF HUMAN RIGHTS 
INSTITUTIONAL REVIEW BOARD 
Review Form D 
It "no" checked, please explain in writing and attach. 
1. Right to Privacy YES / NO 
Yes 
1.1 Obtained tree and informed voluntary written consent. See appendices 
1.2 Provide for anonymity Yes 
1.3 Information obtained held in confidence Yes 
1.4 When a reasonable possibility exists that others may obtain access to information, 
plans for protecting the confidentiality are explained to the subject. Yes 
2. Right to Self-determination 
2.1 Voluntary consent obtained without overt or covert coercion. Yes 
2.2 Deception of subject or concealment of purpose avoided. Yes 
2.3 When concealment is necessary, it is communicated to the subject and a contract is 
made to inform the subject as the design permits. Not applicable. Since this is a 
retrospective chart review, concealment is not necessary. There will not be any contact or 
communication with the subjects involved in the study. 
2.4 Explanations are not ambiguous and the terminology used is appropriate to the 
subjects level of understanding. Yes 
2.5 Subject free to withdraw consent at any point and informed ol such. Yes 
2.6 Obtained third party written consent if necessary. Yes 
3. Rights of Minors and Legally Incompetent Persons 
3.1 If a minor, informed written consent from parents required and obtained. No. Since 
this is a retrospective chart review, we will obtain written consent from the clinics where 
the information is being collected for the study. 
3.2 If legally incompetent, informed written consent from legal guardian required and 
obtained. No. Since this is a retrospective chart review, we will obtain written consent 
from the clinics where the information is bein^cpllected for the study. 
3.3 Supplemental written consent obtained from minor when minor has capacity to 
comprehend implications of study. Nojsincejhi^^ chart revi£w we will 
obtain written consent from the clinics_wherejte^^ collected for the 
study. 
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4. Right of Conservation of Personal Resources 
4.1 Time, freedom from constraint, and personal resources are not abused. Not 
applicable. Since this is a retrospective chart review, the researchers will have no contact 
with the participants. 
4.2 Subject is informed about the nature, extent, and possible consequences of study. No. 
Since this is a retrospective chart review, the researchers will have no contact with the~~ 
participants. 
5. Right to Freedom from Arbitrary Hurt 5.1 Subject protected from arbitrary mental 
and/or physical suffering as a result of study. Yes 
6. Right to Freedom from Intrinsic Risk of Injury 
6.1 Subject has full information about proposed investigation if there is a risk of 
emotional and/or physical injury. Not applicable. Since this is a retrospective chart 
review, the researchers will not have any contact with the participants. The results will be 
given to the healthcare providers participating in the study. 
7. Additional Safeguards 
7.1 Deviation from any of the above principles. No. There will be no deviation from the 
above principles. 
7.2 Evidence demonstrated that appropriate expert advice has been received that it is 
acceptable to deviate. No. Since this is a retrospective chart review, there will not be any 
reason to deviate. 
7.3 The researcher has demonstrated that research assistants have been, or will be trained 
in the ethics involved in carrying out the research design. Yes. 
Vice President for Academic Affairs Date 
REFERENCE: ANA Ethical Guidelines APA Ethical Principles University of Michigan, 
Guidelines for the Protection of Human Rights University of Indiana, Gui e incs or t e 
Protection of Human Rights 
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FORM E 
DEFINITIONS OF TERMS USED BY 
INSTITUTIONAL REVIEW BOARD 
Investigator*: 
A graduate student enrolled in or a faculty member who desires to conduct research with 
human rights who 
1. Is representing himself/herself as a student or faculty member. 
Research 1 
Any organized research, research, potentially publishable to include theses and funded 
research. 
Subject 2 
Any individual who may be "at risk" as a consequence of participation as a subject in 
research. 
At Risk 2 
Any individual is considered "at risk" if he may be exposed to harm physical, 
psychological, sociological, or other as a consequence of any activity which goes beyond 
the application of those established and accepted methods necessary to meet his needs. 
Informed Consent 2 
Informed consent is the agreement obtained from a subject, or from his authorized 
representative, to the subject's participation in an activity. 
1 .The basic elements of informed consent are: 
2. A fair explanation of the procedures to be followed, including an identification 
of those which are experimental; 
3.A description of the attendant discomforts and risks; 
4. A description of the benefits to be expected; 
5. A disclosure of appropriate alternative procedures that would be advantageous 
for the subject; 
6.An offer to answer any inquiries concerning the procedures, 
7.An instruction that the subject is free to withdraw his consent and to discontinue 
participation in the study or activity at any time. 
*Any other person conduction research who desires human rights review by this 
Committee. 
1- Mississippi University for Women Faculty Council March 251980. 
2- United States Department of Health, Education, and Welfare: Policy on Protection of 
Human Subjects, 1971. 
Timeline 
Conceptual Phase- August 2012-December 2012 
• Problem identification 
• Literature review 
• Theoretical framework 
Design/Planning Phase- December 2012-January 2013 
• Research design 
• Population specification 
• Sampling plan 
• Data collection plan 
Empirical Phase- February 201 3-April 2013 
• Collection of data 
• Data preparation 
Analytic Phase- May 2013 
• Data Analysis 
• Interpretation of results 
Dissemination Phase-July 2013 
• Presentations of reports 
• Utilization of findings 
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Provost and Vice President for Academic Affairs 
1100 College St. MUW-1603 




February 18, 2013 
Patsy Smyth, DSN 
Mississippi University for Women 
College of Nursing and Speech-Language Pathology 
MUW - 910 
Columbus, Mississippi 39701-5800 
Dear Dr. Smyth: 
I am pleased to inform you that the members of the Institutional Review Board (IRB) 
have reviewed the following proposed research and have approved it as submitted: 
Name of Study: Tdap Screening and Pertussis Prevention 
Throughout the Age Span 
Investigator(s): Cara Harris and Thu Tran 
Research Patsy Smyth 
Faculty/Advisor: 
I wish you much success in your research. 
Sincerely, 
Dan Heimmermann, Ph.D. 




A Tradition of Excellence for Women and Men 
pc: Tammie McCoy, Institutional Review Board Chairman 
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APPENDIX B 
Letter of Consent for Participation in Research Study 
Date: February . 2013 
Name of Clinic: 
Clinic Address: 
City. State, Zip Code: 
Ue are graduate students in the family nurse practitioner program at Mississippi 
University for Women in Columbus, MS. As a program requirement, we are conducting a 
retrospective chart review to assess screening for Tdap immunization as a booster vaccine 
given to 10-12 years olds. We will be assessing documentation for screening and Tdap 
vaccination to preteens age 10-12. The students that are participating in this research 
project include: Cara Harris and Thu Tran. 
Your participation will involve granting us the privilege of reviewing medical 
records of your clients w ith dates of birth between 2001 and 2003. As researchers, we 
understand that we must maintain the confidentiality of all information collected from the 
charts. We agree to refrain from discussing or disclosing any information regarding your 
clients. Each researcher has received Human Insurance Portability and Accountability 
(HIPAA) training and certification. The study includes a retrospective chart review 
following HIPPA guidelines and will not involve human participants. The chart reviews 
will be recorded on a Data Collection Worksheet then entered into a computer data sheet. 
This information will only be accessible by the researchers and their faculty researcher 
advisor. After completion of the project, all physical data will be destroyed appropriately. 
The results of this study may be published; however, neither names nor patient 
information will be identifiable. 
Your participation in this study is strictly voluntary. The possible benefit of your 
participation is that the research project will serve as a quality assurance measure for you. 
The amount of time required for us to review charts and collect data w ill be 
approximately one month. After the research project is complete, we will provide you 
with the results from the study. , „ uQrr;c 
If you have any questions concerning this research study, p ease ca ara1 
(228) 209-2606, Thu Tran (228) 235-9550 or contact the chair of our researc co 
Dr. Patsy Smyth (662) 889-8384. In addition, you may withdraw >'our cons^"^li" h 
Participation in this study at any time by contacting one of us or the chai 
By completing and signing the attached consent form, you g 




I have read this letter of consent and have been given the opportunity to ask questions. I 
give my consent to participate in the above study. 
Clinic Manager Signature Date 
I have read this letter of consent and have been given the opportunity to ask questions. I 
give my consent to participate in the above study. 
Clinic Manager Signature Date 
APPENDIX C 
Data Collection Worksheet 
Chart# 
1 • Age: 
2. Gender: (0) Male (1) Female 
3. Ethnicity: (0) African American (1) Caucasian (2) Other 
4. Is the patient screened for the need of Tdap Vaccine? 
5. Has vaccine been given? Dates of administration of pertussis-containing 
6. Does the clinic have Tdap and Pertussis educational information? 
